Novartis presented Phase 2 data indicating its recently approved urticaria drug Rhapsido produced favorable immunologic responses in food allergy patients across three dose levels. Company briefings reported higher rates of desensitization markers versus control, positioning Rhapsido for potential label expansion into food allergy. The readout is preliminary and centered on surrogate immune endpoints; larger confirmatory studies and safety monitoring in allergic populations are anticipated.